What are the recent financial highlights of ALIVUS LIFE SCIENCES LTD?

ALIVUS LIFE SCIENCES LTD recently reported a total revenue of ₹2,273.94 Cr and a net profit margin of 19.42%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of ALIVUS LIFE SCIENCES LTD?

ALIVUS LIFE SCIENCES LTD offers a dividend yield of 3.71%, with a dividend rate of ₹43.5 per share.

What are the key financial metrics of ALIVUS LIFE SCIENCES LTD?

Key financial metrics include a trailing P/E ratio of 26.176962, forward P/E of 19.106417, book value of ₹207.199, price-to-book ratio of 4.540562, and a market capitalization of ₹115.38 billion.

What does ALIVUS LIFE SCIENCES LTD do?

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.

Is ALIVUS LIFE SCIENCES LTD a good investment?

Investment decisions should be based on thorough research. ALIVUS LIFE SCIENCES LTD has a P/E ratio of 26.176962, market cap of ₹11,538.06 Cr, and pays dividends of 3.71%. Consult a financial advisor for personalized advice.

Which sector does ALIVUS LIFE SCIENCES LTD belong to?

ALIVUS LIFE SCIENCES LTD operates in the sector, specifically in the industry. This sector has shown volatility in recent years.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Alivus

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Alivus

Latest updates related to Alivus

Sr No.	Title	Sentiment
1	Glenmark Life Sciences renamed as Alivus Life Sciences Business Standard	🔄
2	Alivus Life Sciences to invest more in research, in its new avatar BusinessLine	🔄
3	Alivus Life Sciences delivers 12% revenue growth Indian Pharma Post	🔄
4	Alivus Life Sciences Plans to Ramp Up R&D Investments \| Chemical Industry Digest	🔄
5	Stocks in news: Ambuja Cement, Alivus Life, Route Mobile, Aurobindo Pharma, LTIMindtree The Economic Times	🔄
6	Alivus Life Sciences Limited \| Stock Share Price Live MarketSmith India	🔄
7	Glenmark Life Sciences rebrands as Alivus Life Sciences Medical Dialogues	🔄
8	Alivus Life Standalone December 2024 Net Sales at Rs 641.84 crore, up 12.05% Y-o-Y Moneycontrol	🔄
9	Alivus Life Sciences Reports Strong Q3FY25 Results; Caution Advised on Valuation Investing.com India	🔄
10	Alivus Life Q3 results: Net profit rises to Rs 137 cr, revenue jumps 12% Business Standard	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

Explore More Stocks

NAVA AVL TERASOFT ZAGGLE GINNIFILA JPASSOCIAT PRECISION DIAMINESQ MVKAGRO TASTYBITE